IBEX Technologies Inc.

IBEX Technologies Inc.

IBXNF

IBXNFIBEX Technologies Inc. US flag

Other OTC

1.00

USD

-0.07

- -

25.27MMarket Cap

ISIN

CA4489375085

Return %

Stock

S&P500

1Y

78.57

26.53

3Y

232.90

76.60

5Y

777.19

80.11

Use logarithmic scale

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Company Description

CEO: Paul Baehr
Sector: Healthcare
Industry: Biotechnology
Address: 5485 Rue Pare Montreal QC Canada H4P 1P7
IPO Date: Aug 24, 2018
Website: ibex.ca
Similar Companies: Cellectar Biosciences, Inc. (CLRB)
Entasis Therapeutics Holdings Inc. (ETTX)
Ainos, Inc. (AIMD)
ZIVO Bioscience, Inc. (ZIVOW)
BioCardia, Inc. (BCDAW)
Anew Medical, Inc. (WENA)
Business: IBEX Technologies Inc., now operating as a specialized subsidiary of BBI Solutions OEM Limited, focuses on the development and production of high-purity enzymes for biomedical applications. The company, based in Montreal, Canada, where it was established in 1972, provides its offerings to clients across Canada, the United States, Germany, the United Kingdom, and various international markets. Its core product line encompasses recombinant glycosaminoglycan lyases, featuring enzymes such as Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B. Additionally, IBEX Technologies manufactures collagen ELISAs designed for researching connective tissue synthesis and degradation, alongside a selection of collagen antibodies and diamine oxidase liquid. The company also contributes to osteoarthritis research through its array of arthritis assays. Beyond its product portfolio, IBEX Technologies extends its expertise through various services. These include lyophilization services for fabricating disposable medical device components, custom fermentation, and contract manufacturing solutions for specialized reagents. The company primarily serves manufacturers of medical devices, quality control laboratories, producers of low molecular weight heparin, and academic research institutions. IBEX Technologies Inc.'s shares were delisted from the TSX Venture Exchange following its acquisition by BBI Solutions in April 2024.

Company News